Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies

Investigational Site Number :1580003, Taipei

Investigational Site Number :1580006, Taipei

Investigational Site Number :1580004, Taipei

Investigational Site Number :1580002, Tainan City

Investigational Site Number :1580005, Kaohsiung City

Investigational Site Number :0560001, Brussels

Investigational Site Number :0560002, Ghent

Investigational Site Number :2030002, Prague

Investigational Site Number :3800003, Rozzano

Investigational Site Number :3800009, Milan

Investigational Site Number :7240003, Madrid / Madrid

Investigational Site Number :7240007, Madrid

Investigational Site Number :7240004, Madrid

Investigational Site Number :7240008, Pamplona

Investigational Site Number :3800004, Padua

Investigational Site Number :3800007, Meldola

Investigational Site Number :2030001, Brno

Investigational Site Number :8400002, Houston

Investigational Site Number :2030003, Olomouc

Investigational Site Number :8400004, Santa Monica

Investigational Site Number :8400007, Boston

Investigational Site Number :1240001, Toronto

Investigational Site Number :5280001, Rotterdam

Investigational Site Number :7240001, Barcelona

Investigational Site Number :7240006, Hospitalet de Llobregat

Investigational Site Number :1580001, Taipei